These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 10769676

  • 1. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL, Ling YF, Lai MD.
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [Abstract] [Full Text] [Related]

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
    Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S, Saya H.
    Oncogene; 1998 Feb 19; 16(7):933-43. PubMed ID: 9484785
    [Abstract] [Full Text] [Related]

  • 4. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR.
    Head Neck; 2004 Oct 19; 26(10):870-7. PubMed ID: 15390206
    [Abstract] [Full Text] [Related]

  • 5. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
    Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ.
    Int J Oncol; 2009 Aug 19; 35(2):401-16. PubMed ID: 19578756
    [Abstract] [Full Text] [Related]

  • 6. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines.
    Chang FL, Lai MD.
    Anticancer Res; 2000 Aug 19; 20(1A):351-5. PubMed ID: 10769679
    [Abstract] [Full Text] [Related]

  • 7. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.
    Chang FL, Lai MD.
    J Urol; 2001 Jul 19; 166(1):304-10. PubMed ID: 11435891
    [Abstract] [Full Text] [Related]

  • 8. Phosphorylated and hypoacetylated mutant p53 enhances cisplatin-induced apoptosis through caspase-9 pathway in the absence of transcriptional activation or translation.
    Lai MD, Lin WC, Sun YM, Chang FL.
    Int J Mol Med; 2005 Apr 19; 15(4):725-34. PubMed ID: 15754039
    [Abstract] [Full Text] [Related]

  • 9. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.
    Gynecol Oncol; 2002 Mar 19; 84(3):404-12. PubMed ID: 11855878
    [Abstract] [Full Text] [Related]

  • 10. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K, Li Z, Seth P, Cowan KH, Sinha BK.
    Oncol Res; 1997 Mar 19; 9(11-12):603-9. PubMed ID: 9563008
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene.
    Seki T, Ohba N, Makino R, Funatomi H, Mitamura K.
    Anticancer Res; 2001 Mar 19; 21(3B):1919-24. PubMed ID: 11497278
    [Abstract] [Full Text] [Related]

  • 12. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM.
    Cancer Res; 1994 Nov 15; 54(22):5824-30. PubMed ID: 7954409
    [Abstract] [Full Text] [Related]

  • 13. Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis.
    Raffo AJ, Kim AL, Fine RL.
    Oncogene; 2000 Dec 14; 19(54):6216-28. PubMed ID: 11175336
    [Abstract] [Full Text] [Related]

  • 14. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.
    Cell Growth Differ; 1999 Jul 14; 10(7):473-8. PubMed ID: 10437915
    [Abstract] [Full Text] [Related]

  • 15. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
    Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS.
    Oncogene; 1995 Oct 05; 11(7):1217-28. PubMed ID: 7478541
    [Abstract] [Full Text] [Related]

  • 16. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
    Jin Z, Guan T, Li S.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun 05; 19(3):218-20. PubMed ID: 12048682
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C.
    Mol Pharmacol; 1998 May 05; 53(5):819-26. PubMed ID: 9584207
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.
    Gjerset RA, Lebedeva S, Haghighi A, Turla ST, Mercola D.
    Cell Growth Differ; 1999 Aug 05; 10(8):545-54. PubMed ID: 10470854
    [Abstract] [Full Text] [Related]

  • 19. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
    Tsuchiya H, Mori Y, Ueda Y, Okada G, Tomita K.
    Anticancer Res; 2000 Aug 05; 20(1A):235-42. PubMed ID: 10769661
    [Abstract] [Full Text] [Related]

  • 20. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
    Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schönthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV.
    Clin Cancer Res; 1998 May 05; 4(5):1315-22. PubMed ID: 9607592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.